Clinical data | |
---|---|
Trade names | Albenza, Eskazole, Valbazen, Zentel, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610019 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | <5%[2] |
Protein binding | 70%[2] |
Metabolism | Liver[2] |
Elimination half-life | 8–12 hours[2] |
Excretion | Bile duct (humans) Kidney (ruminants) |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.995 |
Chemical and physical data | |
Formula | C12H15N3O2S |
Molar mass | 265.33 g·mol−1 |
3D model (JSmol) | |
Melting point | 208 to 210 °C (406 to 410 °F) |
| |
| |
(verify) |
Albendazole is a broad-spectrum antihelmintic and antiprotozoal agent of the benzimidazole type.[3] It is used for the treatment of a variety of intestinal parasite infections, including ascariasis, pinworm infection, hookworm infection, trichuriasis, strongyloidiasis, taeniasis, clonorchiasis, opisthorchiasis, cutaneous larva migrans, giardiasis, and gnathostomiasis, among other diseases.[3]
Common side effects include nausea, abdominal pain, and headache.[3] Rare but potentially serious side effects include bone marrow suppression which usually improves on discontinuing the medication. Liver inflammation has been reported and those with prior liver problems are at greater risk.[3] It is pregnancy category D in Australia, meaning it may cause harm if taken by pregnant women.[3][4]
Albendazole was developed in 1975. [5] It is on the World Health Organization's List of Essential Medicines.[6]
plumb
was invoked but never defined (see the help page).MSR
was invoked but never defined (see the help page).